New Type 2 Diabetes Drug Aims to Reduce Risk of Diminished Kidney Function and Cardiovascular Complications

Finerenone (Kerendia) has been approved to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.